- Home
- LVTX vs FLYX Comparison
LVTX vs FLYX Comparison
Compare LVTX & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- FLYX
- Stock Information
- Founded
- LVTX 2016
- FLYX 2015
- Country
- LVTX Netherlands
- FLYX United States
- Employees
- LVTX N/A
- FLYX N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- FLYX Blank Checks
- Sector
- LVTX Health Care
- FLYX Finance
- Exchange
- LVTX Nasdaq
- FLYX Nasdaq
- Market Cap
- LVTX 33.9M
- FLYX 39.4M
- IPO Year
- LVTX 2021
- FLYX N/A
- Fundamental
- Price
- LVTX $1.42
- FLYX $2.25
- Analyst Decision
- LVTX Hold
- FLYX
- Analyst Count
- LVTX 3
- FLYX 0
- Target Price
- LVTX $1.75
- FLYX N/A
- AVG Volume (30 Days)
- LVTX 48.5K
- FLYX 12.4K
- Earning Date
- LVTX 08-19-2025
- FLYX 08-13-2025
- Dividend Yield
- LVTX N/A
- FLYX N/A
- EPS Growth
- LVTX N/A
- FLYX N/A
- EPS
- LVTX N/A
- FLYX N/A
- Revenue
- LVTX $4,990,000.00
- FLYX $335,427,000.00
- Revenue This Year
- LVTX N/A
- FLYX $28.47
- Revenue Next Year
- LVTX N/A
- FLYX $22.44
- P/E Ratio
- LVTX N/A
- FLYX N/A
- Revenue Growth
- LVTX N/A
- FLYX 5.38
- 52 Week Low
- LVTX $0.85
- FLYX $1.79
- 52 Week High
- LVTX $2.21
- FLYX $4.90
- Technical
- Relative Strength Index (RSI)
- LVTX 52.65
- FLYX 42.22
- Support Level
- LVTX $1.33
- FLYX $2.15
- Resistance Level
- LVTX $1.67
- FLYX $2.59
- Average True Range (ATR)
- LVTX 0.13
- FLYX 0.24
- MACD
- LVTX 0.00
- FLYX 0.00
- Stochastic Oscillator
- LVTX 25.00
- FLYX 34.75
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.